Form 4: Arbutus Biopharma CEO Reports Stock Transaction
Insider Transaction (Form 4)
Lindsay Androski, President and CEO and a Director of Arbutus Biopharma Corp, reported multiple transactions in common stock on September 18, 2026.
Summary
- Option exercise/conversion: acquired 116,408 Common Shares at $3.20 ($372,506) on September 18, 2026; holds 144,408 after (Direct).
- Option exercise/conversion: acquired 10,456 Common Shares at $4.39 ($45,902) on September 18, 2026; holds 154,864 after (Direct).
- Tax/exercise-price withholding: disposed of 82,527 Common Shares at $5.07 ($418,412) on September 18, 2026; holds 72,337 after (Direct).
- Option exercise/conversion: disposed of 116,408 Stock Option (Right to Buy) on September 18, 2026; holds 194,014 after (Direct).
- Option exercise/conversion: disposed of 10,456 Stock Option (Right to Buy) on September 18, 2026; holds 61,244 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Lindsay Androski — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Option exercise/conversion | Common Shares | 116,408 | $3 | $372.5K | 144,408 |
| 2026-09-18 | Option exercise/conversion | Common Shares | 10,456 | $4 | $45.9K | 154,864 |
| 2026-09-18 | Tax/exercise-price withholding | Common Shares | 82,527 | $5 | $418.4K | 72,337 |
| 2026-09-18 | Option exercise/conversion | Stock Option (Right to Buy) | 116,408 | — | — | 194,014 |
| 2026-09-18 | Option exercise/conversion | Stock Option (Right to Buy) | 10,456 | — | — | 61,244 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Option exercise/conversion (116,408 shares) |
| 2026-09-18 | Option exercise/conversion (10,456 shares) |
| 2026-09-18 | Tax/exercise-price withholding (82,527 shares) |
| 2026-09-18 | Option exercise/conversion (116,408 shares) |
| 2026-09-18 | Option exercise/conversion (10,456 shares) |
Keywords
insider transaction, Form 4, ABUS, Arbutus Biopharma Corp, neutral, Lindsay Androski
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.